Early in the use of certain purified dextran solutions as plasma volume expanders in the treatment of shock in man, it was observed that immediate type allergic reactions could be produced (1) (2) (3) (4) . The then available clinical dextrans of Swedish and British origin had been found to give a high incidence of allergic reactions, while a product of American manufacture produced a very low incidence (3, 4). The reason for this difference remained obscure.
shown that a significant proportion of individuals showed small amounts of precipitating antibody to dextran (cf. 13) and wheal and erythema type sensitivity before any known deliberate contact with dextran.
In view of the interest in dextran solution as a plasma volume expander in the therapy of shock, and since the basis of the systemic reactions to dextran was not understood, and methods of commercial manufacture of dextran solution frequently failed to yield products which did not produce allergic reactions, it became important to evaluate the possible role of existing skin sensitivity and circulating antibody to dextran in relation to systemic reactions to infusions of dextran in a group of normal individuals. A cooperative study sponsored by the Subcommittee on Shock of the National Research Council and the Armed Services was undertaken. ' Earlier findings (3, 4) were confirmed that the incidence of generalized allergic reactions varied quite sharply with the type of dextran and manufacturing process used at that time. With a dextran giving a high incidence of systemic allergic reactions on intravenous infusion, a high statistical correlation was found between allergic reactions and initial skin sensitivity to certain native dextrans and also between allergic reactions and initial circulating precipitin levels as determined with certain dextrans. Clinical dextrans gave a low incidence of positive skin test reactions, whereas native dextrans gave a high incidence of positive reactions. Hehre and Neill (cited in Reference 2) had noted some positive skin reactions to native dextran in man.
A correlation between the incidence of skin sensitivity and the structure of the native dextran was also found. From an interpretation of the 1160 findings, it became possible to define the basis of specifications for clinical dextran manufacture with respect to selection of Leuconostoc mesenteroides strain, and upper and lower limits of molecular size. Adherence to these specifications permitted the manufacture of dextran giving a negligible incidence of allergic reactions in clinical use.
METHODS

Materials
A. Clinical dextrans for infusion were: High, 7.8 per cent 100,000 Low, 7.9 per cent 30,000 Swedish dextran was produced by a strain of L. mesenteroides which yielded a native dextran (3079') with 88 per cent 1-*6-like, 5 per cent 1-*4-like and 7 per cent 1->3-like linkages, giving a ratio of 1-*6 to non-1--6 linkages of 7.5 (14) , while the Commercial Solvents Corporation dextran was prepared from the NRRL B512 strain which yielded a dextran containing 96 per cent of 1-+6 linkages and 4 per cent of 1->3-like linkages (15) 
Experimental subjects
Two hundred and seven Air Force inductees, 17 to 26 years of age, who had never received an infusion of dextran volunteered for the experiment. From 51 of these the routine course of immunization required on induction was withheld until after the completion of the study. In addition, 33 subjects who had received dextran infusions from 4 to 23 months previously in earlier studies (3, 4) volunteered to receive a second infusion. The combined results of the two studies carried out three months apart in January and April, 1952, are presented.
Design of experiment
Studies were carried out in a ward at the Lackland Air Force Base Hospital, San Antonio, Texas, except for a small number of the re-infusions which were carried out at the Walter Reed Army Medical Center, Washington, D. C. Groups of approximately 50 subjects were studied at one time. An initial blood sample of 200 ml. was taken sterilely. The serum from these bleedings was prepared, frozen and shipped to Dr. Paul H. Maurer at the University of Pittsburgh by air express. Upon receipt of the sera, phenol to 0.25 per cent and merthiolate to a concentration of 1: 10,000 were added and the sera kept frozen until used. Each subject then received nine intracutaneous inj ections of the various native or clinical dextrans, Leuconostoc protein, or phenolized saline along both arms. The 101 subjects in the first study were not skin tested with Leuconostoc (10) (11) (12) . Although 3.0 ml. of serum was used for each analysis the results are expressed in micrograms of antibody nitrogen per ml. of serum.
RESULTS
Results as presented are a summary of the findings. Complete observations on each individual and the antibody analyses appear in the reports to the National Research Council. Table I shows the incidence of skin sensitivity to the various dextrans used for skin tests in individuals who showed positive and negative systemic reactions. Figure 1 summarizes the distribution among the systemic reactors and non-reactors with respect to the severity of the skin test. The degree of the systemic reactions is also indicated. It is clearly evident from Table I that there is a high degree of correlation between systemic allergic reactions to infusion of Swedish dextran and previously existing skin sensitivity to native Swedish dextran and to native dextrans NRRL B1255 and B742. Native NRRL B512 and the two clinical dextrans gave much lower incidences of initial skin sensitivity and no correlation with systemic reactions was found.
In B512 and to clinical Swedish dextran in the second of the two groups studied. A breakdown of the distribution of skin reactions is given in Table  II for these two experiments.
It is also of interest that the incidence of positive skin tests of individuals before infusion of dextran was higher with those native dextrans having a higher proportion of non 1->6 linkages. The proportion of positive skin tests was unrelated to the nitrogen content of the native dextrans, B742 with the lowest nitrogen giving the highest incidence of positive skin reactions. Table III summarizes data on the relation between systemic allergic reactions and circulating precipitins to various dextrans before infusion and one month after infusion of dextran.
In the pre-infusion series with Swedish dextran, significant correlations between the presence of 2 jug. of antibody N or more per ml. precipitable by native dextrans NRRL B742, NRRL B512 and Swedish 3079 were found. In the post-infusion series significant correlations were found with these dextrans and with NRRL B1254. In Experiment 2 in which Commercial Solvents dextran was infused, significant correlations were found between systemic reactions and the presence of 2 ,pg. or more of antibody N per ml. precipitable by native B512, clinical Commercial Solvents dextran and clinical Swedish dextran. No correlation with any dextran appeared in the post-infusion sera.
It should be noted that as previously reported (10, 11) the quantities of antibody N precipitable from a given serum specimen by the various dextrans were not identical, but the dextrans with the highest proportion of non 1-*6 linkages precipitated considerably more antibody than did those with fewer non 1--6 linkages. Native dextran NRRL B742 with the lowest nitrogen content precipitated the most antibody of the various infusion of either Swedish or Commercial Sol-precipitating antibodies to dextran. This preparavents dextran within the time interval studied did tion from a strain of Leuconostoc (NRRL B512) not result in any enhanced susceptibility to allergic yielded a dextran having the lowest incidence of reactions on re-infusion of dextran. Three of the non-1-*6 linkages (15) and hence was the most four positive reactions which resulted on re-in-linear dextran available. Furthermore, in the fusion of Swedish dextran were of the same de-random population native dextran from this strain gree of severity as had previously been noted showed the lowest incidence of wheal and erythema from the first infusion of Swedish dextran. The skin reactions of any of the native dextrans tested. fourth individual showed only one hive from the With respect to circulating precipitins, however, second infusion. the number of individuals showing two or more DISCUSSION micrograms of antibody N per ml. was about the The results outlined above clearly established same for native Swedish, native B512 and native that it is possible to produce a dextran suitable B1254 dextrans and these were considerably for clinical use which gives a low incidence of fewer than the number of individuals showing 2 allergic reactions in a population, a large propor-or more micrograms of antibody N per ml. with tion of which showed initial skin sensitivity of the B742. Partial hydrolysis of Swedish or Comwheal and erythema type and whose sera contained mercial Solvents dextrans to produce a dextran suitable for use as a plasma volume expander produced a dramatic reduction in the capacity of the material to induce wheal and erythema reactions or to precipitate the circulating antidextran in the same population (Tables II and III) . It is noteworthy that the dextran which produced the lowest incidence of allergic reactions (CSC 255F4) had been sharply fractionated to remove materials of high molecular weight, while the dextran which gave the high incidence of allergic reactions (Swedish) had not been so fractionated and contained appreciable quantities of materials with very high molecular weights. The lot containing intermediate-sized material (CSC 258A7) gave two severe reactions in thirty individuals tested. In an independent study, Kabat and Bezer (18) have shown that a substantial decrease in antigenicity of B512 dextran occurs with molecular weights below 90,000, and Maurer (12) has reported definite antigenicity for dextran 258A7
obtaining levels of about 10 or more pg. antibody N per ml. in three of six individuals injected. It would then appear that choice of dextran producing microorganism, degree of hydrolysis, and extent of removal of high molecular weight constituents are important factors in the manufacture of reaction-free dextran.
The occurrence of precipitins to dextran and of initial skin sensitivity to dextran in the population raise the question as to the origin of these antibodies. Since dextran has been shown by Neill, Hehre, Sugg, and Jaffe (19, 20) to be a contaminant of commercial sugar, and since these workers have isolated dextran-producing organisms from the gastrointestinal tract (21, 22) , ample opportunity exists for the development of an antibody response. Furthermore, since dextrans are known to cross-react with Types II, XII, XX, IX, XXII, etc. rabbit and horse antipneumococcal sera (19, 20, 23) , the precipitable antibody and skin sensitivity to dextran in human subjects may theoretically in some instances be attributable to previous contact or infection with these organisms. On the other hand, Maurer (12) found that immunization of humans with dextran did not affect the Type II, XII or XX antipolysaccharide levels, nor did absorption with Type II, XII, or XX pneumococcal polysaccharides reduce the antidextran level. It is not surprising that a linear dextran should give a lower incidence of skin sensitivity than a more highly branched dextran, since the latter would possess a multiplicity of structures not present in the former and thus would increase the probability of its being able to react with antibodies produced to the heterogenous array of antigenic stimuli encountered at random in the human environment.
Although the data clearly indicate a high statistical correlation between initial skin sensitivity to native dextrans and systemic allergic reactions, there are a sufficient number of exceptions so that the single skin test of 10 to 20 micrograms of dextran was of little prognostic significance in evaluating the occurrence of allergic reaction in response to injection of 30 Gm. of dextran. This is not surprising since a) the nature of the antigen to which the initial skin sensitivity developed is not known and, in all probability, is not the same as that used for skin test and infusion; b) the ratio of the infused dose to the skin test dose is unusually high, of the order of three million; c) only a single skin test dose was used.
Similar considerations obviously apply to the individual cases in which precipitating antibody levels and allergic reactions did not run parallel, although again a high statistical correlation was observed between these levels and allergic reactions. Thus the capacity of the various dextrans to precipitate the multiplicity of antibodies resulting from the unknown antigenic stimuli and the necessarily limited capacity to establish optimum quantities of dextran for precipitating these antibodies in the quantitative precipitin studies would contribute substantially to such individual variations.
The finding of an anamnestic rise in antibody level one month after infusion of Swedish dextran in a considerable proportion of individuals while no such rise was observed following infusion of Commercial Solvents dextran is in accord with evidence suggesting that the latter is less antigenic in man, although MacLeod (24) has found that the pneumococcus polysaccharides are capable of eliciting an anamnestic response in the rabbit despite their inability to produce a primary antibody response.
While the limited re-infusion data indicate that dextran may be re-infused up to 23 months following an initial infusion without difficulty, it is obviously impossible to extrapolate to periods be-yond this. The generally lower antigenicity of the current commercial preparations of dextran prepared from the B512 strain according to American specifications provide additional assurance of its probable safety for clinical use. It should be emphasized that the Swedish preparations herein described were in use in [1951] [1952] . The current preparations of Swedish dextran differ in two important respects from these older preparations in that they are prepared from the B512 strain and are more sharply fractionated to remove high molecular weight constituents. SUMMARY 1. A detailed protocol for elucidating the relationship between skin sensitivity and precipitating antibody in the random population to a carbohydrate antigen and their relation to the occurrence of allergic reactions on intravenous administration is described.
2. Significant correlations were established between a) initial skin sensitivity to certain native dextrans and the occurrence of systemic allergic reactions on administration of Swedish dextran; b) the presence in human sera of antibodies specifically precipitable by certain dextrans and the occurrence of systemic allergic reactions to clinical Swedish dextran; c) the structural complexity of native dextrans and the incidence of positive skin sensitivity in the random population.
3. Partial hydrolysis of native dextrans to the molecular weight range suitable for clinical use results in a striking diminution in their capacity to produce a positive wheal and erythema reaction in man. 4 . In a population of comparable skin sensitivity and antibody levels a preparation of clinical dextran (Commercial Solvents) was encountered which gave a very low incidence of systemic allergic reactions. This appeared to be correlated with the selection of a strain of Leuconostoc mesenteroides (NRRL B512) producing a dextran with an unusually low proportion of non 1--6 linkages and with the elimination of materials of higher molecular weight range by fractional precipitation to give a product with a narrower molecular weight distribution. 5 . In a small series of individuals receiving reinfusion of both Swedish and Commercial Solvents dextran no evidence of increased sensitization was found during an interval of up to 23 months between the two infusions.
